Patients with previously untreated advanced squamous non-small-cell lung cancer lived significantly longer without their ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed. | ...

The discussion transitions to biomarker testing as an essential component of lung cancer diagnosis, with Dr. Florez ...

A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to ...

An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small ...

Phase 3 data on sunvozertinib for EGFR exon 20 insertions and sacituzumab tirumotecan plus pembrolizumab for PD-L1-positive ...

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...

If you have non-small-cell lung cancer (NSCLC) with an EGFR mutation, your health care provider may recommend a new medicine called Datroway (datopotamab deruxtecan-dlnk). NSCLC is the most common ...

Substantial EFS improvement with selpercatinib in RET fusion-positive disease ...

Adhering to the current guideline standard for intraoperative nodal assessment in resected non–small cell lung cancer (NSCLC) ...

FDA fast-tracks VS-7375, an oral KRAS G12D inhibitor, opening new hope for pretreated advanced NSCLC and fueling pivotal ...